Asset Details
Do you wish to reserve the book?
Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease
Do you wish to request the book?
Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease
2013
Overview
In increasingly aging populations, awareness of outcomes of older patients treated with biologics is becoming more important. However, few studies to date have investigated the safety and durability of anti-tumor necrosis factor (TNF) therapy in this subgroup.MethodsThis was a retrospective single-center study with cases comprising all IBD patients who began anti-TNF treatment at age >60 years. Cases of Crohn's disease (CD) and ulcerative colitis (UC) were identified from medical record review. Our controls consisted of patients younger than age 60 years on anti-TNF treatment and patients >60 years on treatment with immunomodulators. Kaplan–Meier survival estimates were used to calculate the probability of remaining on anti-TNF therapy.ResultsWe identified a total of 54 IBD patients who initiated anti-TNF therapy over the age of 60 years (mean 73, range 61–97 years). Among these, a total of 38 patients (70%) discontinued anti-TNF therapy after a mean of 24.1 months. At 12 months after initiation, 75% of patients older than age 60 years were still on anti-TNF agents compared to 93% among younger users and 82% among older AZA users (P < 0.05). Compared to older AZA users, older anti-TNF users remained more likely to require early therapy cessation (hazard ratio 2.21, 95% confidence interval 1.29–3.78).ConclusionsThe IBD population older than age 60 at the time of initiation of anti-TNF therapy is at higher risk for discontinuation of therapy. They may also be particularly vulnerable to infectious complications requiring hospitalization, suggesting the need for careful monitoring during therapy.
Publisher
Oxford University Press
Subject
/ Adult
/ Age
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Azathioprine - therapeutic use
/ Colitis, Ulcerative - drug therapy
/ Crohn Disease - drug therapy
/ Female
/ Humans
/ Immunoglobulin Fab Fragments - adverse effects
/ Immunoglobulin Fab Fragments - therapeutic use
/ Immunosuppressive Agents - adverse effects
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Mercaptopurine - therapeutic use
/ Polyethylene Glycols - adverse effects
